Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer

18 Nov 2023

Abstract excerpt

The molecular underpinnings of HER2-low and HER2-0 (IHC 0) breast tumors remain poorly defined. Using genomic findings from 1039 patients with HER2-negative metastatic breast cancer undergoing next-generation sequencing from 7/2013-12/2020, we compare results between HER2-low (n = 487, 47%) and HER2-0 tumors (n = 552, 53%). A significantly higher number of ERBB2 alleles (median copy count: 2.05) are observed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to HER2/EGFR in Cancer Research
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37980405
DOI: 10.1038/s41467-023-43324-w

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comprehensive genomic characterization of HER2-low and HER2-0 breast cancerPMID 37980405Read ↗

Genomic Alterations of Tumors in HER2-Low Breast Cancers.Semantic proximity Read ↗

Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer.Semantic proximity Read ↗

Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas.Semantic proximity Read ↗

Genomic landscape of circulating tumor DNA in HER2-low metastatic breast cancer.Semantic proximity Read ↗

Clinical and molecular characteristics of HER2-low triple-negative breast cancer: insights from multi-omics analysisSemantic proximity Read ↗

Clinicopathological features and prognosis of HER2 low-expression breast cancer: a single-center retrospective studySemantic proximity Read ↗

Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast Cancers.Semantic proximity Read ↗

Clinical sequencing defines the somatic and germline mutation landscapes of Chinese HER2-Low Breast Cancer.Semantic proximity Read ↗

Next-generation sequencing in breast cancer: current clinical applications and future directionsSemantic proximity Read ↗

Exploring the Heterogeneity of HER2 gene status and Expression in Non-Positive Breast Cancer Patients: Insights from Immunohistochemistry and Fluorescence In Situ HybridizationSemantic proximity Read ↗

Molecular and clinical traits of HER2-low breast cancer patients and their relationship with neoadjuvant treatment effectiveness.Semantic proximity Read ↗

Epigenetic determinants of an immune-evasive phenotype in HER2-low triple-negative breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.